Literature DB >> 9731696

Beta-blockers for chronic heart failure: from prejudice to enlightenment.

J G Cleland1, J McGowan, P J Cowburn.   

Abstract

Experience accumulated from several large trials strongly suggest that beta-blockers should be used for the management of congestive heart failure (CHF). Beta-blockade should be added to conventional therapy such as diuretics, ACE inhibitors, and digoxin, as this was the approach used in the major trials. It is appropriate to treat patients with mild, moderate and, when stable, severe CHF. The benefits obtained include improvements in left ventricular function, reductions in symptoms and morbidity, improvement of quality of life, and delay of clinical progression, reflected by a reduced need for hospitalization and a reduction in mortality. Beta-blockers are much better tolerated, when used appropriately in selected patients, than was previously supposed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9731696     DOI: 10.1097/00005344-199800003-00009

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  3 in total

Review 1.  Should beta-blockers be used for the treatment of pediatric patients with chronic heart failure?

Authors:  Luke A Bruns; Charles E Canter
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

2.  Bucindolol: a pharmacogenomic perspective on its use in chronic heart failure.

Authors:  Neil A Smart; Nigel Kwok; David J Holland; Rohan Jayasighe; Francesco Giallauria
Journal:  Clin Med Insights Cardiol       Date:  2011-06-28

Review 3.  Carvedilol in the treatment of elderly patients with chronic heart failure.

Authors:  Klaus K A Witte; Andrew L Clark
Journal:  Clin Interv Aging       Date:  2008       Impact factor: 4.458

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.